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Abstract We examined the effects of two novel 1K,25-
dihydroxyvitamin D3-26,23-lactone (1K,25-(OH)2D3-26,23-lac-
tone) analogs on 1K,25(OH)2D3-induced differentiation of
human leukemia HL-60 cells thought to be mediated by the
genomic action of 1K,25-dihydroxyvitamin D3 (1K,25-(OH)2D3)
and of acute promyelocytic leukemia NB4 cells thought to be
mediated by non-genomic actions of 1K,25-(OH)2D3. We found
that the 1K,25-(OH)2D3-26,23-lactone analogs, (23S)-25-dehy-
dro-1K-hydroxyvitamin D3-26,23-lactone (TEI-9647) and (23R)-
25-dehydro-1K-hydroxyvitamin D3-26,23-lactone (TEI-9648),
inhibited differentiation of HL-60 cells induced by 1K,25-
(OH)2D3. However, 1L-hydroxyl diastereomers of these analogs,
i.e. (23S)-25-dehydro-1L-hydroxyvitamin D3-26,23-lactone (1L-
TEI-9647) and (23R)-25-dehydro-1L-hydroxyvitamin D3-26,23-
lactone (1L-TEI-9648), did not inhibit differentiation of HL-60
cells caused by 1K,25-(OH)2D3. A separate study showed that
the nuclear vitamin D receptor (VDR) binding affinities of the
1-hydroxyl diastereomers were about 200 and 90 times weaker
than that of 1K-hydroxyl diastereomers, respectively. Moreover,
none of these lactone analogs inhibited NB4 cell differentiation
induced by 1K,25-(OH)2D3. In contrast, 1L,25-dihydroxyvitamin
D3 (1L,25-(OH)2D3) and 1L,24R-dihydroxyvitamin D3 (1L,24R-
(OH)2D3) inhibited NB4 cell differentiation but not HL-60 cell
differentiation. Collectively, the results suggested that 1-hydro-
xyl lactone analogs, i.e. TEI-9647 and TEI-9648, are antagonists
of 1K,25-(OH)2D3, specifically for the nuclear VDR-mediated
genomic actions, but not for non-genomic actions.
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1. Introduction
1K,25-Dihydroxyvitamin D3 (1K,25-(OH)2D3) regulates a
wide variety of biological functions. It is widely accepted
that the fundamental activities of 1K,25-(OH)2D3 are to stim-
ulate intestinal calcium absorption and to increase bone cal-
cium mobilization [1,2]. In recent years, many other new bio-
logical functions di¡erent from those mentioned above have
been reported [3]. These include inhibition of cell proliferation
and induction of cell di¡erentiation [4], modulation of immu-
nological responses [5], stimulation of insulin secretion [6,7]
and neurobiological functions [8,9]. 1K,25-(OH)2D3 is believed
to mediate biological responses as a consequence of its inter-
action with both a nuclear vitamin D receptor (VDR) to reg-
ulate gene transcription [10,11] and with a putative membrane
receptor to generate rapid non-genomic e¡ects [12], including
opening voltage-gated calcium and chloride channels [13] and
activation of mitogen-activated protein kinase [14].
A considerable number of vitamin D analogs has been syn-
thesized and the use thereof has prompted the clari¢cation of
the mode of action of vitamin D and the ¢nding of new
therapeutically useful compounds [3]. To date, however, an-
tagonists of vitamin D that oppose the VDR/vitamin D-re-
sponsive element (VDRE)-mediated genomic actions of 1K,25-
(OH)2D3 have not been reported. Very recently, we found
that the two novel 1K,25-dihydroxyvitamin D3-26,23-lactone
(1K,25-(OH)2D3-26,23-lactone) analogs, (23S)-25-dehydro-1K-
hydroxyvitamin D3-26,23-lactone (TEI-9647) and (23R)-25-
dehydro-1K-hydroxyvitamin D3-26,23-lactone (TEI-9648), in-
hibit human leukemia cell (HL-60) di¡erentiation induced by
1K,25-(OH)2D3 [15]. These results strongly suggested that
TEI-9647 and TEI-9648 might be antagonists of VDR/
VDRE-mediated genomic actions of 1K,25-(OH)2D3, because
HL-60 cell di¡erentiation initiated by 1K,25-(OH)2D3 is be-
lieved to occur through a VDR/VDRE-mediated pathway
[16]. On the other hand, it was not clear whether these two
analogs could also antagonize 1K,25-(OH)2D3-mediated rapid
non-genomic actions.
Bhatia et al. reported that 1K,25-(OH)2D3 and a 6-s-cis-
locked analog (1K,25-7-dehydrocholesture), thought to be a
selective activator of non-genomic actions, primed human
acute promyelocytic leukemia cells (NB4 cells) for 12-O-tetra-
decanoylphorbol-13-acetate (TPA)-induced monocytic di¡er-
entiation [17,18]. In these reports, 1K,25-(OH)2D3 action
was considered to be independent of 1K,25-(OH)2D3-VDR
binding and mediated via a VDR/VDRE-independent path-
way [17,18,19]. They also reported that 1L,25-(OH)2D3 could
suppress 1K,25-(OH)2D3 action in NB4 cells. Norman et al.
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reported that 1L,25-(OH)2D3 acted as an antagonist of vita-
min D3-mediated rapid non-genomic actions [20]. From these
data, the NB4 cell di¡erentiation system is regarded as a
model for characterization of non-genomic actions or their
signaling pathway(s) [17].
In this paper, we report the e¡ect of the novel 1K,25-
(OH)2D3-26,23-lactone analogs, TEI-9647 and TEI-9648, on
1K,25-(OH)2D3-mediated non-genomic actions using the NB4
cell di¡erentiation system. These analogs were found to sup-
press 1K,25-(OH)2D3-mediated HL-60 cell di¡erentiation but
not NB4 cell di¡erentiation. On the contrary, 1L,25-(OH)2D3
and 1L,24R-dihydroxyvitamin D3 (1L,24R-(OH)2D3) sup-
pressed NB4 cell di¡erentiation caused by 1K,25-(OH)2D3.
These results suggest that TEI-9647 and TEI-9648 might be
the ¢rst antagonists speci¢c for 1K,25-(OH)2D3-mediated ge-
nomic actions but not for non-genomic actions.
2. Materials and methods
2.1. Chemicals
1K,25-(OH)2D3, 1L,25-(OH)2D3, 1L,24R-(OH)2D3, TEI-9647, TEI-
9648, (23S)-25-dehydro-1L-hydroxyvitamin D3-26,23-lactone (1L-TEI-
9647) and (23R)-25-dehydro-1L-hydroxyvitamin D3-26,23-lactone (1L-
TEI-9648) were synthesized in our laboratory as described previously
[21,22]. The chemical structures of these compounds are shown in Fig.
1. TPA was purchased from Wako Pure Chemical Industries (Osaka,
Japan). Nitro blue tetrazolium (NBT) was purchased from Tokyo
Kasei kogyo (Tokyo, Japan). [26,27-methyl-3H]1K,25-(OH)2D3 (spe-
ci¢c activity, 180 Ci/mmol) was purchased from Amersham Interna-
tional (Little Chalfont, Buckinghamshire, UK).
2.2. Cell and cell culture
HL-60 cells were obtained from the Japanese Cancer Research Re-
sources Bank. NB4 cells were obtained from K.A. Meckinling-Gill
(University of Guelph, Ont., Canada). Cells were passaged twice a
week to maintain the exponential proliferating phase. RPMI 1640
(Gibco BRL, Life Technologies, Rockville, MO, USA) containing
10% heat-inactivated fetal bovine serum (FBS) (Bioserum, Lot No.
01307-01) was used as culture medium.
2.3. Binding a⁄nity to VDR
A competitive receptor binding assay for 1K,25-(OH)2D3 and
1K,25-(OH)2D3-26,23-lactone analogs was performed using chick in-
testinal VDR as described previously [23,24]. [26,27-Methyl-3H]1K,25-
(OH)2D3 (speci¢c activity, 180 Ci/mmol) and various amounts of the
1K,25-(OH)2D3-26,23-lactone analogs to be tested were dissolved in
50 Wl of absolute ethanol in 12U75 mm polypropylene tubes (Sar-
stedt, Nu«mbrecht, Germany). One ml of the chick intestinal cytosol
receptor protein diluted to 0.2 mg protein/ml in phosphate bu¡er
(25 mM KH2PO4, 0.1 M KCl, 1 mM dithiothreitol, pH 7.4) and
1 mg of gelatin were added to each tube in an ice bath. The assay
tubes were incubated in a shaking water bath for 1 h at 25‡C and then
chilled in an ice bath. One ml of 40% (w/v) polyethylene glycol 6000 in
distilled water was added to each tube, which was then mixed vig-
orously and centrifuged at 2260Ug for 60 min at 4‡C. After the super-
natant was decanted, the bottom of the tube containing the pellet was
cut o¡ into a scintillation vial containing 10 ml of dioxane-based
scintillation £uid consisting of 10% naphthalene and 0.5% Omni£uor
(DuPont, Boston, MA, USA) in 1,4-dioxane. The radioactivity was
measured in a Beckman liquid scintillation counter (Model LS6500)
using an external standard.
2.4. Cell di¡erentiation assay (NBT reducing activity)
NBT reducing activity was used as a cell di¡erentiation marker.
HL-60 cells and NB4 cells were cultured in RPMI 1640 medium
supplemented with 10% FBS. Exponentially proliferating cells were
collected, suspended in fresh medium, seeded in culture vessels and
treated with various amounts of 1K,25-(OH)2D3 and 1K,25-(OH)2D3-
26,23-lactone analogs. Twenty-four well culture plates (Falcon, Bec-
ton Dickinson and Company, Franklin Lakes, NJ, USA) were used.
In the HL-60 cell di¡erentiation assay, cells were treated with the
compounds for 96 h at 37‡C in a humidi¢ed atmosphere of 5%
CO2/air without medium change. In the NB4 cell di¡erentiation assay,
cells were treated with 1K,25-(OH)2D3 and 1K,25-(OH)2D3-26,23-lac-
tone analogs for 8 h, then washed and re-suspended in media con-
taining 3U10310 M TPA for up to 72 h. In both cell lines, the cell
concentration at seeding was adjusted to 2U104 cells/ml and the
seeded volume was 1 ml/well. 1K,25-(OH)2D3 and 1K,25-(OH)2D3-
26,23-lactone analogs were dissolved in ethanol and added to the
culture medium at 0.1% volume. The same amount of vehicle was
added to the control culture. The NBT reduction assay was performed
according to the method of S.J. Collins et al. [25]. Brie£y, cells were
collected and washed with phosphate-bu¡ered saline (PBS). After
washing, cells were suspended in serum-free medium and NBT/TPA
Fig. 1. Structures of 1L,25-(OH)2D3, 1L,24R-(OH)2D3 and 1K,25-(OH)2D3-26,23-lactone analogs.
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solution (dissolved in PBS) was added. Final concentrations of NBT
and TPA were 0.1% and 100 ng/ml, respectively. Then, the cell sus-
pension was incubated at 37‡C for 25 min. After incubation, cells
were collected by centrifugation and re-suspended in PBS. Cytospin
smears were prepared and the nuclei were counterstained with Kern-
echtrot solution. At least 500 cells per preparation were observed.
3. Results
Fig. 1 indicates the structure of 1K,25-(OH)2D3, 1L,25-
(OH)2D3, 1L,24R-(OH)2D3 and 1K,25-(OH)2D3-26,23-lactone
analogs. TEI-9647 and TEI-9648 are both 25-dehydrated lac-
tones of the (23S,25R)- and (23R,25R)-1K,25-(OH)2D3-26,23-
lactone, respectively. Formally, TEI-9647 and TEI-9648 are
23-diastereoisomers of one another. 1L-TEI-9647 and 1L-
TEI-9648 are 1L-hydroxyl diastereomers of TEI-9647 and
TEI-9648, respectively.
The receptor binding of 1L,25(OH)2D3, 1L,24R-(OH)2D3
and 1K,25-(OH)2D3-26,23-lactone analogs is shown in Table
1. The chick intestinal VDR binding a⁄nities of TEI-9647
and TEI-9648 were about 10 and 7%, respectively, as com-
pared with 1K,25-(OH)2D3. In contrast, the VDR binding
a⁄nities of 1L-TEI-9647 and 1L-TEI-9648 were about 200
and 90 times weaker than their 1K-hydroxyl diastereomers.
The binding a⁄nities of 1L-25-(OH)2D3 and 1L,24R-(OH)2D3
were 0.3 and 0.4%, respectively, as compared with 1K-25-
(OH)2D3.
Bhatia et al. showed that treatment with 1K,25-(OH)2D3 or
TPA alone could not induce NB4 cell di¡erentiation. How-
ever, combined treatment with both compounds induced NB4
cell di¡erentiation [17,18]. Also, they reported that 1L,25-
(OH)2D3 inhibited cell di¡erentiation induced by 1K,25-
(OH)2D3. In agreement with their results, we con¢rmed that
treatment with 1038 M 1K,25-(OH)2D3 or 10310 M TPA alone
could not induce cell di¡erentiation. However, treatment with
1038 M 1K,25-(OH)2D3 followed by 3U10310 M TPA did
induce di¡erentiation (Fig. 2). In addition, we also con¢rmed
that 1036 M 1L,25-(OH)2D3 potently inhibited cell di¡erentia-
tion induced by 1K,25-(OH)2D3 (Fig. 2). Interestingly, NB4
cell di¡erentiation caused by 1K,25-(OH)2D3 was also inhib-
ited by the addition of the 24-hydroxyl analog of 1L,24R-
(OH)2D3 (Fig. 2). Both 1L,25- and 1L,24R-(OH)2D3 showed
similar dose-dependent response curves, but the inhibition ef-
fect of 1L,24R-(OH)2D3 was weaker than that of 1L,25-
(OH)2D3 (Fig. 3A). On the contrary, HL-60 cell di¡erentia-
tion induced by 1K,25-(OH)2D3 was not inhibited by either
1L,25-(OH)2D3 or 1L,24R-(OH)2D3 (Fig. 3B).
Fig. 2. NB4 cell di¡erentiation induced by 1K,25-(OH)2D3 and TPA. NB4 cells were treated with 1038 M 1K,25-(OH)2D3 or vehicle (ethanol
0.1% v/v) for 8 h, were then washed and re-suspended in media containing 3U10310 M TPA or vehicle (ethanol 0.1% v/v) for up to 72 h.
NBT reducing activity was examined as described in Section 2. (A) Vehicle control. (B) 1K,25-(OH)2D3 for 8 h followed by vehicle for up to
72 h. (C) Vehicle for 8 h followed by TPA for up to 72 h. (D) 1K,25-(OH)2D3 for 8 h followed by TPA for up to 72 h. (E) 1036 M 1L,25-
(OH)2D3 was added to media during 1K,25-(OH)2D3 treatment. (F) 1036 M 1L,24R-(OH)2D3 was added to media during 1K,25-(OH)2D3 treat-
ment.
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Next, we examined the e¡ect of lactone analogs on HL-60
or NB4 cell di¡erentiation induced by 1K,25-(OH)2D3. Nei-
ther TEI-9647 nor TEI-9648 inhibited NB4 cell di¡erentiation
(Fig. 4A). 1L-TEI-9647 and 1L-TEI-9648, 1L-hydroxyl diaster-
eomers of TEI-9647 and TEI-9648, respectively, also did not
inhibit (Fig. 4A). We also examined agonistic e¡ects of the
four lactone analogs, but none of them induced NB4 cell
di¡erentiation (data not shown). Both TEI-9647 and TEI-
9648 inhibited 1K,25-(OH)2D3-induced HL-60 cell di¡erentia-
tion dose-dependently (Fig. 4B). However, the 1L-hydroxyl
diastereomers, 1L-TEI-9647 and 1L-TEI-9648, did not inhibit
di¡erentiation even after treatment with 1036 M. The agonist
e¡ect of the four lactone analogs was also examined, but none
of them induced HL-60 cell di¡erentiation (data not shown).
4. Discussion
We recently reported that the novel lactone analogs, TEI-
9647 and TEI-9648, could inhibit the di¡erentiation of HL-60
cells induced by 1K,25-(OH)2D3 [15]. Because HL-60 cell dif-
ferentiation is believed to be mediated through a VDR/
VDRE-dependent pathway [16], we considered that TEI-
9647 and TEI-9648 might be antagonists of VDR-mediated
genomic actions of 1K,25-(OH)2D3. Ozono et al. have pre-
sented direct evidence that TEI-9647 could antagonize the
transactivation function of VDR elicited by 1K,25-(OH)2D3
([26], in preparation). However, it was not clear whether
TEI-9647 and TEI-9648 also function as antagonists of
1K,25-(OH)2D3-mediated non-genomic actions.
The di¡erentiation of NB4 cells is considered to be a good
model for 1K,25-(OH)2D3-mediated non-genomic actions
[17,18]. Therefore, we examined the e¡ects of TEI-9647 and
TEI-9648 on NB4 cell di¡erentiation induced by 1K,25-
(OH)2D3 to evaluate their antagonistic activity to non-ge-
nomic actions. As shown in Fig. 4A, neither analogs could
inhibit NB4 cell di¡erentiation. In this study, we also exam-
ined their antagonist activity for 1K,25(OH)2D3-mediated HL-
60 cell di¡erentiation and con¢rmed our previous results (Fig.
4B). Moreover, in agreement with a previous report [20], we
found that 1L,25-(OH)2D3, the speci¢c antagonist of 1K,25-
Table 1
Binding a⁄nities of vitamin D3 analogs to VDR in various cells
Vitamin D3 analogs Relative activity
Chick intestinal VDR MG-63 cells VDR HL-60 cells VDR
1K,25(OH)2D3 100.0 100.0 100.0
1L,25(OH)2D3 0.4 0.1 n.e.
1L,24R(OH)2D3 0.3 0.3 n.e.
TEI-9647 10.2 7.9 9.9
TEI-9648 7.2 6.0 8.5
1L-TEI-9647 0.05 0.03 n.e.
1L-TEI-9648 0.08 0.03 n.e.
TEI-9616 0.5 0.6 0.4
(23S,25R)-1K,25(OH)2D3-26,23-lactone 0.1 0.07 0.07
n.e. : not examined. The relative activity for each analog was calculated from their respective EC50 results and then normalized to the result ob-
tained for 1K,25(OH)2D3, which was set to 100%.
Fig. 3. E¡ects of 1L,25-(OH)2D3 and 1L,24R-(OH)2D3 on NB4 cell di¡erentiation (A) or HL-60 cell di¡erentiation (B). (A) NB4 cells were
treated with 1038 M 1K,25-(OH)2D3 in the absence (3) or presence (1039^1036 M) of 1L,25-(OH)2D3 or 1L,24R-(OH)2D3 for 8 h and re-sus-
pended in media containing 3U10310 M TPA for up to 72 h and NBT reducing activity was examined. (B) HL-60 cells were treated with 1038
M 1K,25-(OH)2D3 in the absence (3) or presence of 1L,25-(OH)2D3 or 1L,24R-(OH)2D3 (1036 M) for 96 h and NBT reducing activity was ex-
amined. Vehicle control cultures (0) were treated with ethanol (added 0.1% v/v). Rectangles and bars show mean þ S.D. of triplicates, respec-
tively.
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(OH)2D3-mediated non-genomic actions, clearly inhibits NB4
cell di¡erentiation (Fig. 3A). The results described above sug-
gested that TEI-9647 and TEI-9648 are not antagonists of
1K,25-(OH)2D3-mediated non-genomic actions, but of VDR/
VDRE-mediated genomic actions.
1L-TEI-9647 and 1L-TEI-9648, 1K-hydroxyl diastereomers
of TEI-9647 and TEI-9648, respectively, did not antagonize
HL-60 cell di¡erentiation (Fig. 4B). We also found that in-
version of the 1K-hydroxyl groups to the 1L-orientation re-
sulted in a dramatic change in their receptor binding a⁄nities
(Table 1). A⁄nities of 1L-TEI-9647 and 1L-TEI-9647 for
VDR were about 1/100^1/200 of TEI-9647 or TEI-9648. The
detailed mechanism of the antagonistic action of the lactone
analogs is not yet completely elucidated, but Norman et al.
have suggested that TEI-9647 binding to the VDR would not
elicit the conformational change of helix 12 required for trans-
activation [27]. Conformational change of helix 12 after ligand
(1K,25-(OH)2D3) binding to VDR is perceived to be impor-
tant for interaction with co-activators, such as steroid receptor
co-activator-1, and elicitation of transactivation [27,28]. Col-
lectively, these results suggest that receptor binding a⁄nity
may be important for the antagonistic e¡ect of TEI-9647
and TEI-9648 on VDR/VDRE-mediated genomic action.
Therefore, the fact that 1L-TEI-9647 and 1L-TEI-9648 could
not inhibit HL-60 cell di¡erentiation may be mainly due to
their weak binding a⁄nity to receptors.
Norman et al. synthesized various A-ring diastereomers of
1K,25-(OH)2D3 and reported that the orientation of carbon-1
and -3 hydroxyl groups would be important for genomic or
non-genomic actions [20]. Interestingly, they reported that
1L,25-(OH)2D3 was a potent antagonist of 1K,25-(OH)2D3-
mediated non-genomic responses. In this study, we found
that 1L,24R-(OH)2D3 also showed antagonistic activity to
non-genomic action (Fig. 3A) but not to genomic action
(Fig. 3B). These results indicated that the L-orientation of
the carbon-1 hydroxyl group may play an important role
for antagonism of non-genomic actions. However, 1L-TEI-
9647 and 1L-TEI-9648, which possess a 1L-hydroxyl group
but have a side-chain structure di¡erent from 1L,25-(OH)2D3,
did not show antagonistic activity to non-genomic actions
(Fig. 4A). As yet, the speci¢c factors or receptors which me-
diate the non-genomic actions of 1K,25-(OH)2D3 are not yet
clear. However, these results suggest that both the orientation
of carbon-1 and the side-chain structure may be important in
antagonism of non-genomic actions and both would a¡ect
a⁄nity for the putative receptors or factors of the non-ge-
nomic actions.
In conclusion, our data demonstrate that the novel lactone
analogs, TEI-9647 and TEI-9648, may be antagonists of
VDR/VDRE-mediated genomic actions but not of non-ge-
nomic actions. They are the ¢rst speci¢c antagonists of
1K,25-(OH)2D3-mediated genomic action. Comparison of the
antagonistic activity of 1L,25-(OH)2D3 and combination stud-
ies of these antagonists can be expected to advance our under-
standing of structure-function relationships in ligands and re-
ceptors interaction and function.
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